NCT01071928View on ClinicalTrials.gov

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Urothelial Carcinoma
Interventions
DRUG

Docetaxel

Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1

DRUG

ASA404

ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Hoosier Cancer Research Network

OTHER